Home // eTELEMED 2015, The Seventh International Conference on eHealth, Telemedicine, and Social Medicine // View article

Benefit of Telemedicine for Patients with Diabetes Mellitus

Authors:
Irene Tagliente
Matteo Ritrovato
Nicola Ullmann
Francisco. J. Leon Trujillo
Riccardo Schiaffini

Keywords: Type 1 diabetes, Adolescence, Telemedicine, CSII, SAP

Abstract:
The mean HbA1c difference between Sensor Augmented Pump (SAP) therapy and Multiple Daily Injections (MDI) is 0.3 to 0.6% in favour of SAP, but adolescents, although treated with SAP therapy, show a progressive temporary deterioration of glucose control. Telemedicine in Type 1 Diabetes is thought to facilitate diabetes management and to improve compliance to CSII/SAP treatment especially during adolescence. The aim of the present study was to observe the long term impact on glycometabolic control of Telemedicine systems compared with traditional follow-up in Type 1 diabetes SAP treated adolescents. The observed HbA1c decrease in the group followed with telemedicine was associated with a better compliance to therapy in terms of frequency of sensor use, number of SMBG tests and number of insulin boluses. When Telemedicine was added to SAP Therapy, we may assist adolescents living with type 1 diabetes to become more compliant to self-management of the disease. More and wider studies are needed in order to confirm this data and better define populations appropriate for the Telemedical approach.

Pages: 151 to 154

Copyright: Copyright (c) IARIA, 2015

Publication date: February 22, 2015

Published in: conference

ISSN: 2308-4359

ISBN: 978-1-61208-384-1

Location: Lisbon, Portugal

Dates: from February 22, 2015 to February 27, 2015